Cystectomy for bladder cancer in elderly patients is not associated with increased 30- and 90-day mortality or readmission, length of stay, and cost: propensity score matching using a population database

Wei-Yu Lin,1–3,* Chun-Te Wu,3,4 Miao-Fen Chen,3 Ying-Hsu Chang,6 Cheng-Li Lin,7,8 Chia-Hung Kao9–11,*
1Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chia-Yi, Taiwan; 2Nursing Department, Chang Gung University of Science and Technology, Chia-Yi, Taiwan; 3Department of Medicine, Chang Gung University, Taoyuan, Taiwan; 4Department of Urology, Chang Gung Memorial Hospital, Keelung, Taiwan; 5Department of Radiation Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan; 6Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, LinKo, Taiwan; 7Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan; 8School of Medicine, China Medical University, Taichung, Taiwan; 9Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan; 10Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan; 11Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan

*These authors contributed equally to this work

Purpose: Radical cystectomy (RC) is an effective but underused treatment for bladder cancer in elderly patients. This study performed analysis of propensity scores (PSs) to determine the outcomes of RC for elderly patients, with results generalizable at the population-based level.

Patients and methods: We conducted a population-based, retrospective cohort study of patients who underwent RC in Taiwan during 2000–2010. Multivariable logistic regression was implemented to evaluate 30- and 90-day mortality and readmission rates, length of intensive care unit (ICU) stay, length of hospital stay (LOS), and cost. Enrolled patients were divided into younger (≤75 years) and older groups (>75 years) who were matched according to their PSs.

Results: We identified 430 patients with bladder cancer who underwent RC between 2000 and 2010. Older age was not significantly associated with 30-day readmission (odds ratio [OR] = 0.80, 95% confidence interval [CI] = 0.38–1.70), 90-day readmission (OR = 1.10, 95% CI = 0.60–2.00), 30-day mortality (OR = 3.07, 95% CI = 0.31–30.0), or 90-day mortality (OR = 2.98, 95% CI = 0.91–9.70) in the PS-matched group. Similar trends were also observed for both groups regarding the mean length of ICU stay, LOS, and overall medical expenditure within the same admission.

Conclusion: No significant differences existed between the older and younger groups for 30- and 90-day mortality and readmission rates, length of ICU stay, LOS, and medical expenditure in patients undergoing RC for bladder cancer. Some healthy elderly patients may be good candidates for this extensive curative treatment.

Keywords: cystectomy, bladder cancer, elderly, mortality, readmission, cost

Introduction

Because of the close association between age and incidence of cancer, it is believed that 70% of cancer diagnoses will be made in people aged 65 years or older in the US by 2030.1 Bladder cancer occurs more often in elderly patients than in younger adults; those older than 70 years have a sevenfold to tenfold increased likelihood.2 With populations becoming more aged, treating people with cancer will be vital in the years ahead. Radical cystectomy (RC) is the standard treatment for patients with muscle-invasive and refractory cancer.3 Although extensive transurethral resection and external radiation therapy in conjunction with systemic chemotherapy have emerged as valid treatment options,4 these alternatives are unlikely to provide a cure and may
only extend an individual’s disease-free survival without prolonging their overall survival.\(^5\) However, RC can have substantial morbidity, mainly in vulnerable older adults. This surgery is associated with an incidence of postoperative complications of up to 60% and 90-day mortality of approximately 5%–15%;\(^4\) therefore, physicians tend not to administer this form of treatment in patients aged 75 years or older.\(^1\) Approximately 25% of patients with bladder cancer who are 70–79 years of age undergo RC.\(^5\) Nevertheless, after adjustment for tumor grade and stage, RC was associated with the greatest reduction in risk of death from bladder cancer in a previous study (the hazard ratio was 0.3 for cancer-specific survival and 0.4 for all-cause survival).\(^5\)

Although old age has been determined not to be a risk factor for bladder cancer after RC, detailed data regarding the potential association are lacking. Recognizing the factors that affect postoperative outcome is essential for individual risk adjustment prior to RC. Several studies have reported predictors of complications, perioperative mortality, and readmission.\(^7\)–\(^11\) However, the data are usually obtained from tertiary referral centers, and the results may not be generalizable on a population-based level.

Recent population-based studies have reported nationwide outcomes for patients treated with RC for bladder cancer.\(^7\)–\(^13\)\(^,\)\(^14\) However, current metrics for quality of care, such as the 30-day and 90-day readmission rates, length of intensive care unit (ICU) stay, length of hospital stay (LOS), and cost, are still lacking, especially for a propensity score (PS)-matched population-based study. Such data would be helpful in assessing the potential risks and benefits of RC, particularly with the current demographic shift that will lead to an increase in unhealthy and elderly patients.

This study performed PS analysis to determine the outcomes of RC for elderly patients, with results generalizable at the population-based level.

**Patients and methods**

**Data source**

This study used data obtained from the Registry of Catastrophic Illnesses Patient Database (RCIPD) extracted from the National Health Research of the Taiwan National Health Insurance (NHI) program. The NHI program was launched in March 1995 and provides comprehensive and universal health insurance to all citizens of Taiwan.\(^13\) The RCIPD contains registration files and original medical claims data for all beneficiaries, with encryption of unique personal identification to secure patient confidentiality. The details of the RCIPD and NHI program have been provided in previous studies.\(^16\)\(^,\)\(^17\) Diagnoses were made using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. This study was approved by the ethics review board of China Medical University (CMUH 104-REC2-115).

**Sample participants**

From the RCIPD, we identified patients with bladder cancer (ICD-9-CM code 188.9) who were older than 20 years and had undergone RC, including open RC and laparoscopic RC, between 2000 and 2010. The index date was the date on which the patient underwent RC. We excluded patients who were aged younger than 20 years and those with missing data for date of birth or sex. Patients with bladder cancer were classified into two age groups: younger (≤75 years) and older (>75 years). Within each group, patients were matched according to their PSs. The PS was calculated using logistic regression to estimate probabilities between different age group assignments based on the baseline variables: age, monthly income (USS), occupation, urbanization level, index year, and comorbidities of hypertension (ICD-9-CM codes 401-405), ischemic heart disease (ICD-9-CM codes 410-414), chronic obstructive pulmonary disease (ICD-9-CM codes 491, 492, and 496), asthma (ICD-9-CM code 493), and stroke (ICD-9-CM codes 430–438).

**Outcome measurements**

All patients with bladder cancer who underwent RC were followed from the date of RC to death, withdrawal from the insurance program, or the end of 2011. Postoperative complications were defined to involve readmission within 30 or 90 days and mortality within 30 or 90 days after discharge. We also estimated length of ICU stay, LOS, and overall admission expenditure within the same surgery admission between the younger and older groups.

**Statistical analyses**

Baseline characteristics were compared between the younger and older groups by using the chi-square test for categorical variables and the two sample t-test for continuous variables. The Kaplan–Meier method was used to plot the survival curves during the follow-up period, and the log-rank test was used to assess the differences between these curves. Univariate and multivariable logistic regression analyses were used to evaluate the effects of age on the risk of 30- or 90-day readmission and 30-day or 90-day mortality, as indicated by the odds ratios (ORs) and 95% confidence intervals (CIs). All statistical analyses were performed using SAS 9.4 (SAS
Institute Inc., Cary, NC, USA). The significance level for all analyses was set to a \( p \)-value of 0.05.

**Results**

Table 1 lists the baseline characteristics and comorbidity statuses of the patients in the nonmatched and PS-matched cohorts. We identified 430 patients with bladder cancer who underwent RC between 2000 and 2010; we included these patients in the nonmatched cohort. The mean ages of the younger and older groups were 63.3 and 79.2 years, respectively. Both groups tended to have monthly incomes <US$500 (60.5% vs. 60.4%) and worked in blue-collar jobs; comorbidities were more common in the older group, except for asthma and stroke. However, the PS-matched younger and older groups were similar in all baseline characteristics except age. The Kaplan–Meier analysis revealed that the probability of freedom from mortality was not significantly different between the younger and older groups (Figure 1). Table 2 presents the ORs of the postoperative complications associated with age. Older age patients were significantly associated with an increased risk of 90-day mortality (OR = 3.71, 95% CI = 1.52–9.07) compared with the younger patients; however, correlations with other postoperative complications, including 30-day readmission after discharge (OR = 0.74, 95% CI = 0.38–1.46), 90-day readmission after discharge (OR = 0.90, 95% CI = 0.54–1.49), and 30-day postoperative mortality (OR = 3.50, 95% CI = 0.78–15.7),

![Figure 1](https://example.com/figure1.png)

**Table 1** Demographic characteristics and comorbidity in patients with bladder cancer who underwent cystectomy, with and without PS matching

| Variable                  | Non-matching | p-value | PS matching   | p-value |
|---------------------------|--------------|---------|---------------|---------|
|                           | \( \leq 75 \) years | \( >75 \) years | \( \leq 75 \) years | \( >75 \) years |
| Age (years), mean (SD)    | 63.3 (8.53)  | 79.2 (3.69)  | \( <0.001 \) | 0.74 |
| Monthly income (US$), n (%) | <500  | 196 (60.5)  | 64 (60.4)  | \( <0.001 \) | 0.74 |
|                           | 500–667  | 29 (8.95)  | 12 (11.3)  | 12 (12.5)  | 11 (11.5)  |
|                           | \( \geq 667 \)  | 99 (30.6)  | 30 (28.3)  | 25 (26.0)  | 26 (27.1)  |
| Occupation, n (%)         | 0.004     | 0.76     |               |         |
| White collar              | 151 (46.6)  | 34 (32.1)  | 35 (36.5)  | 33 (34.4)  |
| Blue collar               | 157 (48.5)  | 59 (55.7)  | 53 (55.2)  | 52 (54.2)  |
| Others^                  | 16 (4.94)  | 13 (12.3)  | 8 (8.33)  | 11 (11.5)  |
| Urbanization level, n (%) | 0.001     | 0.93     |               |         |
| 1 (highest)               | 72 (22.2)  | 12 (11.3)  | 12 (12.5)  | 12 (12.5)  |
| 2                         | 107 (33.0)  | 24 (22.6)  | 20 (20.8)  | 23 (24.0)  |
| 3                         | 55 (17.0)  | 31 (29.3)  | 27 (28.1)  | 28 (29.2)  |
| 4 (lowest)               | 90 (27.8)  | 39 (36.8)  | 37 (38.5)  | 33 (34.4)  |
| Comorbidity, n (%)        |               |         |               |         |
| Hypertension              | 177 (54.6)  | 82 (77.4)  | \( <0.001 \) | 75 (78.1)  | 72 (75.0)  | 0.61 |
| IHD                       | 77 (23.8)  | 44 (41.5)  | \( <0.001 \) | 32 (33.3)  | 34 (35.4)  | 0.76 |
| COPD                      | 52 (16.1)  | 43 (40.6)  | \( <0.001 \) | 32 (33.3)  | 33 (34.4)  | 0.88 |
| Asthma                    | 28 (8.64)  | 16 (15.1)  | 0.06       | 12 (12.5)  | 13 (13.5)  | 0.83 |
| Stroke                    | 25 (7.72)  | 13 (12.3)  | 0.15       | 9 (9.38)  | 10 (10.4)  | 0.81 |

**Notes:** Chi-square test. \(^1\) Two-sample t-tests. \(^2\) US dollar (US$1 = NT$30). \(^3\) Urbanization level was categorized according to the population density of the residential area into four levels, with level 1 as the most urbanized and level 4 as the least urbanized. \(^4\) Other occupations included primarily retired, unemployed, or low-income populations. 

**Abbreviations:** COPD, chronic obstructive pulmonary disease; IHD, ischemic heart disease; PS, propensity score; SD, standard deviation.
were not observed in the nonmatched group. Similar trends were observed in the PS-matched group; however, older age was not significantly associated with 90-day mortality risk (OR = 2.98, 95% CI = 0.91–9.70) in the PS-matched group. The mean (and standard deviation [SD]) values of length of ICU stay, LOS, and overall medical expenditure within the same surgery admission in the older group were similar to those in the younger group (Table 3).

Discussion

After considering both perioperative morbidity and mortality, our study supports RC as a realistic option for treating elderly patients, because elderly patients were equally eligible for RC as younger patients. We calculated the 30- versus 90-day mortality rates of the younger and older groups as 1.04% versus 3.13% and 4.17% versus 11.5%, respectively. Therefore, the 30-day mortality may cause gross underestimation of 90-day mortality after RC in both groups. Thus, for a complete risk assessment, 90-day mortality rates may represent the most valuable calculations, rather than 30-day mortality rates.

Compared with younger age, older age was significantly associated with an increased risk of 90-day mortality (OR = 3.71, 95% CI = 1.52–9.07); however, in the PS-matched group, older age was not significantly associated with the risk of 90-day mortality (OR = 2.98, 95% CI = 0.91–9.70). Therefore, age is not a factor of perioperative mortality and should not preclude elderly patients from receiving RC. In particular, compared with other treatment modalities, RC offers patients, even those older than 80 years, the greatest reduction in the risk of death from bladder cancer.18–21 Numerous studies have demonstrated high hospital readmission rates after RC, ranging from 25% to 41%.9,10,22–24 This study found a similar high rate of readmission. Our 30-day readmission rate was similar to that reported by Roghmann et al, who showed that most admissions after RC occurred within 30 days (19.7%).12

Extending the readmission rate analysis beyond the typical 30-day window offers a more thorough comprehension of the morbidity related to RC.25 Specifically, in both the younger and older groups, >30% of patients required hospital readmission within 90 days of surgery, which is

Table 2 Risk of mortality associated with different age groups in patients with bladder cancer in the multivariable logistic regression model, with and without PS matching

| Variable                        | Non-matching, n (%) | OR (95% CI)a | PS matching, n (%) | OR (95% CI)a |
|---------------------------------|---------------------|--------------|--------------------|--------------|
| Cystectomy                      |                     |              |                    |              |
| ≤75 years                       | 324                 | 57 (17.6)    | 0.74 (0.38–1.46)   | 18 (18.8)    |
| >75 years                       | 106                 | 15 (14.2)    | 0.90 (0.54–1.49)   | 15 (15.6)    |
| 30 days readmission after discharge | 57                  | 115 (35.5)   | 3.50 (0.78–15.7)   | 31 (32.3)    |
| 90 days readmission after discharge | 15                  | 35 (33.0)    | 1.04 (0.31–3.0)    | 33 (34.4)    |
| 30-day postoperative mortality  | 50                  | 5 (1.54)     | 3.71 (1.52–9.07)   | 4 (4.17)     |
| 90-day postoperative mortality  | 106                 | 13 (12.3)    | 1.10 (0.60–2.00)   | 11 (11.5)    |

Notes: *Adjusting for age, monthly income, occupation, urbanization level, and comorbidities of hypertension, IHD, COPD, asthma, and stroke. **p < 0.01.

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; IHD, ischemic heart disease; OR, odds ratio; PS, propensity score.

Table 3 Length of ICU stay, LOS, and overall medical expenditure among patients with bladder cancer in different age groups, with and without PS matching

| Variable                        | Non-matching | p-value | PS matching | p-value |
|---------------------------------|--------------|---------|-------------|---------|
| Cystectomy                      |              |         |             |         |
| ≤75 years                       | 324          | 1.33 (9.09) | 0.77 | 0 (0.00) | 1.16 (8.85) |
| >75 years                       | 106          | 1.05 (8.42) | 0.82 | 20.5 (13.1) | 21.7 (12.2) |
| Length of ICU admission         |              |         |             |         |
| Mean (SD), daysa                | 6542.4 (6034.5) | 0.20 | 6273.5 (4916.7) | 0.46 |

Notes: *Two-sample t-tests. **US dollar (US$1 = NT$30).

Abbreviations: ICU, intensive care unit; LOS, length of hospital stay; PS, propensity score; SD, standard deviation.
higher than the approximate rate of 27% of patients with 90-day readmission shown in a previous study.25 However, unlike our nationally based data, the accuracy of readmission rates derived from a single institution is limited by the researchers’ ability to capture readmissions at nonaffiliated institutions. Therefore, readmission data obtained from single-institution studies represent an underestimation of the actual readmission rate.25 The present national-population-based study was free from the aforementioned limitation; therefore, compared with the single-institute study of a tertiary referral center, the 90-day readmission rate in this study was >30% in both the younger and older groups. Unexpectedly, older age was not a risk factor for 30- and 90-day readmission, because no significant difference was observed between the two groups. Because of the lack of details, we could not confirm whether these readmissions resulted from potentially preventable complications or the progression of surgical disease. Nevertheless, one study revealed that only a small percentage of readmitted patients were confirmed to have an evitable complication of their medical care.26 Therefore, the reasons for readmission after RC warrant further examination.

Our results reveal that overall medical expenditure within the same surgery admission in the older group was similar to that in the younger group. Additionally, the mean (SD) values of length of ICU stay and LOS were not significantly different between the groups. To our knowledge, this is the first study to compare the overall medical expenditure for RC between elderly and younger patients with bladder cancer. This information can be a vital reference for designing a health care strategy for an aging population.

Despite its strengths, this study had limitations. The database used in this study did not include clinical information such as disease stage, disease grade, extent of lymphadenectomy, pathologic tumor characteristics, Clavien grades of postoperative complication, surgical approach (open vs. laparoscopy or robot assisted), and urinary diversion (continent or incontinent).

Conclusion

Using PS matching, we demonstrated that the 30- and 90-day mortality, readmission rate, length of ICU stay, LOS, and cost of RC for patients aged >75 years were comparable to those of their younger counterparts. Our results suggest that decisions for RC should not be based on only age because several other factors influence survival outcomes in patients. Some healthy elderly patients may be good candidates for this extensive curative treatment.

Acknowledgments

This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-122-133019); China Medical University Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project (BM10501010037); NRPB Stroke Clinical Trial Consortium (MOST 105-2325-B-039-003); Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.

Author contributions

Wei-Yu Lin and Chia-Hung Kao were involved in study conception and design. All authors carried out analysis and interpretation of data. Wei-Yu Lin and Chia-Hung Kao contributed to preparation of the manuscript. All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Wuethrich PY, Vidal A, Burkhard FC. There is a place for radical cystectomy and urinary diversion, including orthotopic bladder substitution, in patients aged 75 and older: results of a retrospective observational analysis from a high-volume center. Urol Oncol. 2016;34(2):58.e19–e27.
2. Griebling TL. Trends in cancer of the urinary bladder and urinary tract in elderly in Denmark, 2008-2012. J Urol. 2017;197:317.
3. Isbarn H, Jeldres C, Zini L, et al. A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol. 2009;182(1):70–77.
4. Kulkarni GS, Hermanns T, Wei Y, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of multidisciplinary bladder cancer clinic. J Clin Oncol. 2017;35:2299–2305.
5. Shariat SF, Milowsky M, Droller MJ. Bladder cancer in the elderly. Urol Oncol. 2009;27(6):653–667.
6. Shabsigh A, Kores R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55(1):164–174.
7. Gandaglia G, Varda B, Sood A, et al. Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. Can Urol Assoc J. 2014;8(9–10):E681–E687.
8. Roghmann F, Trinh QD, Braun K, et al. Standardized assessment of complications in contemporary series of European patients undergoing radical cystectomy. Int J Urol. 2014;21:143–149.
9. Stimson CJ, Chang SS, Barocas DA, et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010;184(4):1296–1300.
10. Hollenbeck BK, Miller DC, Taub D, et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol. 2005;174(4 pt 1):1231–1237.
11. De Nunzio C, Cindolo L, Leonardo C, et al. Analysis of radical cystectomy and urinary diversion complications with the Clavien classification system in an Italian real life cohort. *Eur J Surg Oncol*. 2013;39(7):792–798.

12. Roghmann F, Sukumar S, Ravi P, et al. Radical cystectomy in the elderly: national trends and disparities in perioperative outcomes and quality of care. *Urol Int*. 2014;92(1):27–34.

13. Bianchi M, Trinh QD, Sun M, et al. Impact of academic affiliation on radical cystectomy outcomes in North America: a population-based study. *Can Urol Assoc J*. 2012;6:245–250.

14. Kim SP, Boorjian SA, Shah ND, et al. Contemporary trends of in-hospital complications and mortality for radical cystectomy. *BJU Int*. 2012;110(8):1163–1168.

15. NHIR. Database NHIR. Taiwan: 2015. Available from: http://nhird.nhri.org.tw/en/index.html. Accessed January 1, 2018.

16. Huang KW, Kuan YC, Luo JC, Lin CL, Liang JA, Kao CH. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. *Eur J Intern Med*. 2016;32:91–95.

17. Lee CW, Lin CL, Sung FC, Liang JA, Kao CH. Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study. *J Clin Psychiatry*. 2016;77(1):117–122.

18. Donat SM, Siegrist T, Cronin A, Savage C, Milowsky MI, Herr HW. Radical cystectomy in octogenarians -- does morbidity outweigh the potential survival benefits? *J Urol*. 2010;183(6):2171–2177.

19. Konety BR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. *J Urol*. 2003;170(5):1765–1771.

20. Schrag D, Mitra N, Xu F, et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. *Urology*. 2005;65(6):1118–1125.

21. Chappidi MR, Kate M, Stinson CJ, et al. Causes, timing, hospital costs and perioperative outcomes of index vs nonindex hospital readmissions after radical cystectomy: implications for regionalization of care. *J Urol*. 2017;197:296–301.

22. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. *Eur Urol*. 2009;55(1):164–174.

23. Stitzenberg KB, Chang Y, Smith AB, Nielsen ME. Exploring the burden of inpatient readmissions after major cancer surgery. *J Clin Oncol*. 2015;33(5):455–464.

24. Skolarus TA, Jacobs BL, Schroock FR, et al. Understanding hospital readmission intensity after radical cystectomy. *J Urol*. 2015;193(5):1500–1506.

25. Lowrance WT, Rumohr JA, Chang SS, Clark PE, Smith JA Jr, Cookson MS. Contemporary open radical Cystectomy: analysis of perioperative outcomes. *J Urol*. 2008;179(4):1313–1318.

26. McIntyre LK, Arbabi S, Robinson EF, Maier RV. Analysis of risk factors for patient readmission 30 days following discharge from general surgery. *JAMA Surg*. 2016;151(9):855–861.